Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Healthy Volunteers
Interventions
DRUG

C-10276

C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose

DRUG

C-10276

C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose

DRUG

C-10297

C-10297 200 mg, oral, single dose

DRUG

C-10299

C-10299 200 mg, oral, single dose

DRUG

C-10297

C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose

DRUG

C-10299

C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose

DRUG

C-10276

C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose

DRUG

Reyataz®

Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY

NCT01458769 - Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz | Biotech Hunter | Biotech Hunter